NASDAQ$CPRX
Catalyst Pharmaceuticals Inc · Q2 2021 earnings
Q2 2021 earnings · · Investor relations
Headline financials
Revenue & EPS history
Catalyst Pharmaceuticals · Revenue · Quarterly
$36.4M
Q2 2021+22.8%vs Q2 2020
Revenue by segment
Catalyst Pharmaceuticals · $153M total across 3 segments · Q4 2025
- FIRDAPSE$97.6M+18.3%64.0%
- AGAMREE$35.3M+67.5%23.1%
- FYCOMPA$19.6M-48.7%12.9%
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q2 2021
-0.7%
Avg return
Earnings day
+5.2%
Avg return
5 days after
+10.3%
Avg return
30 days after
38%
25 / 65 earnings
Positive
+29.1%
Q4 2016
Best reaction
-18.7%
Q1 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -0.0% | +0.1% | — | |
| Q4 2025 | +0.0% | -3.8% | -5.9% | |
| Q3 2025 | -1.9% | +8.0% | +10.1% | |
| Q2 2025 | -10.1% | -6.7% | -6.9% | |
| Q1 2025 | -3.0% | +0.8% | +10.3% | |
| Q4 2024 | +5.2% | +7.4% | +20.0% | |
| Q3 2024 | +5.9% | +6.8% | +0.3% | |
| Q2 2024 | +13.0% | +19.2% | +21.1% | |
| Q1 2024 | +3.4% | +7.1% | +3.2% | |
| Q4 2023 | +11.7% | +16.3% | +11.1% | |
| Q3 2023 | -4.1% | -1.7% | +10.1% | |
| Q2 2023 | +4.8% | +3.7% | -11.1% | |
| Q1 2023 | -18.7% | -24.5% | -33.2% | |
| Q4 2022 | +6.1% | +10.4% | +19.1% | |
| Q3 2022 | +0.7% | +2.7% | +6.8% | |
| Q2 2022 | +20.8% | +27.9% | +40.3% | |
| Q1 2022 | -0.5% | +5.7% | +1.7% | |
| Q4 2021 | -2.0% | +4.1% | +11.5% | |
| Q3 2021 | +2.7% | +18.0% | +4.3% | |
| Q2 2021 | +2.2% | +4.0% | -12.9% | |
| Q1 2021 | -1.9% | +14.1% | +17.2% | |
| Q4 2020 | +6.7% | +12.3% | +14.7% | |
| Q3 2020 | +7.9% | +7.9% | +12.4% | |
| Q2 2020 | -17.5% | -14.3% | -21.7% | |
| Q1 2020 | -5.7% | -6.4% | -6.6% | |
| Q4 2019 | -15.2% | -13.5% | +27.6% | |
| Q3 2019 | -9.6% | -11.6% | -13.9% | |
| Q2 2019 | +0.6% | -1.0% | +30.7% | |
| Q1 2019 | -0.3% | +20.7% | +16.9% | |
| Q4 2018 | +16.8% | +34.9% | +76.5% | |
| Q3 2018 | -4.9% | -14.5% | -26.2% | |
| Q2 2018 | +2.4% | +3.8% | +16.1% | |
| Q1 2018 | +0.7% | +21.2% | +23.4% | |
| Q4 2017 | -9.6% | -10.5% | -18.5% | |
| Q3 2017 | -4.2% | -6.1% | +28.2% | |
| Q2 2017 | -1.4% | +1.4% | -9.7% | |
| Q1 2017 | +2.2% | +12.2% | +32.8% | |
| Q4 2016 | +29.1% | +41.9% | +50.4% | |
| Q3 2016 | +4.0% | +12.9% | +16.8% | |
| Q2 2016 | -1.3% | -3.9% | +33.8% | |
| Q1 2016 | -6.3% | — | — | |
| Q4 2015 | -10.6% | — | — | |
| Q3 2015 | -5.3% | — | — | |
| Q2 2015 | -9.2% | — | — | |
| Q1 2015 | -1.5% | — | — | |
| Q4 2014 | +15.8% | — | — | |
| Q3 2014 | -6.3% | — | — | |
| Q2 2014 | -2.7% | — | — | |
| Q1 2014 | +2.8% | — | — | |
| Q4 2013 | +9.6% | — | — | |
| Q3 2013 | -2.1% | — | — | |
| Q2 2013 | -6.3% | — | — | |
| Q1 2013 | -7.3% | — | — | |
| Q4 2012 | -5.1% | — | — | |
| Q3 2012 | -10.7% | — | — | |
| Q2 2012 | -7.9% | — | — | |
| Q1 2012 | -5.6% | — | — | |
| Q4 2011 | -6.1% | — | — | |
| Q3 2011 | +2.0% | — | — | |
| Q2 2011 | -6.6% | — | — | |
| Q1 2011 | -0.7% | — | — | |
| Q4 2010 | -0.0% | — | — | |
| Q3 2010 | -0.5% | — | — | |
| Q2 2010 | +0.3% | — | — | |
| Q1 2010 | -9.8% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro